Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

Johnson & Johnson, founded in 1886, makes and sells medical devices, pharmaceuticals, and consumer health products. Headquartered in New Brunswick, N.J., the company operates over 250 subsidiary ...

In the latest trading session, Johnson & Johnson (JNJ) closed at $147.77, marking a +1.93% move from the previous day. The stock's performance was ahead of the S&P 500's daily loss of 0.21%. Elsewhere ...

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...

Johnson & Johnson (NYSE:JNJ) Declares a cash payout of $1.24 dividend per share on common stock for first quarter 2025, payable on 4th of March 2025 to shareholders that recorded on 18th of ...

Innovation remains core, seen in new products such as SPRAVATO for depression and the OTTAVA robotic system. Johnson & Johnson recently concentrated on fostering innovations within its segments ...

Sales across other products were only down 1%. In 2020 and 2021 (albeit to a lesser degree in 2021), Johnson and Johnson benefitted from some unique, one-time tax benefits. These benefits did not ...

Leerink Partners analyst Marc Goodman maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...

Johnson & Johnson expects full-year earnings in the range of $10.50 to $10.70 per share, with revenue in the range of $89.2 billion to $90 billion. This story was generated by Automated Insights ( ...

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and ...